18274307. Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277) simplified abstract (The Regents of the University of California)
Contents
- 1 Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277)
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277) - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277)
Organization Name
The Regents of the University of California
Inventor(s)
Alexander Marson of San Francisco CA (US)
Murad Mamedov of San Francisco CA (US)
Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277) - A simplified explanation of the abstract
This abstract first appeared for US patent application 18274307 titled 'Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277)
Simplified Explanation
Described herein are positive and negative regulators of BTN3A, as well as methods for identifying subjects who can benefit from T cell therapies and/or various chemotherapies. The subjects can, for example, be suffering from immune disorders, cancer, and other diseases and conditions.
- Positive and negative regulators of BTN3A identified
- Methods for identifying subjects who can benefit from T cell therapies and/or chemotherapies developed
Potential Applications
This technology could be applied in the following areas:
- Personalized medicine for immune disorders, cancer, and other diseases
- Development of targeted T cell therapies
- Optimization of chemotherapy treatments
Problems Solved
This technology addresses the following issues:
- Identifying suitable candidates for T cell therapies and chemotherapies
- Improving treatment outcomes for immune disorders and cancer
- Personalizing treatment plans based on individual genetic markers
Benefits
The benefits of this technology include:
- Enhanced efficacy of T cell therapies and chemotherapies
- Tailored treatment plans for patients
- Improved patient outcomes and quality of life
Potential Commercial Applications
The potential commercial applications of this technology include:
- Pharmaceutical companies developing targeted therapies
- Diagnostic companies offering genetic testing services
- Healthcare providers offering personalized treatment plans
Possible Prior Art
One possible prior art in this field is the identification of biomarkers for predicting response to immunotherapy in cancer patients. This research laid the foundation for personalized medicine approaches in oncology.
Unanswered Questions
How does this technology compare to existing methods for identifying suitable candidates for T cell therapies and chemotherapies?
This article does not provide a direct comparison with current diagnostic techniques or biomarker assays used in clinical practice.
What are the potential limitations or challenges in implementing this technology in a clinical setting?
The article does not address the practical considerations or regulatory hurdles that may arise when translating this research into clinical applications.
Original Abstract Submitted
Described herein are positive and negative regulators of BTN3A, as well as methods for identifying subjects who can benefit from T cell therapies and/or various chemotherapies. The subjects can for example be suffering from immune disorders, cancer and other diseases and conditions.
